UBS Maintains Buy on Neurocrine Biosciences, Lowers Price Target to $214

Benzinga Newsdesk www.benzinga.com Negative 81.5%

Neg 81.5% Neu 0% Pos 0%

UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and lowers the price target from $231 to $214.